Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Chicago Research Center Inc

Neither a doctor nor a teaching hospital

Research payments

$5,819,646

290 payments

Through program year 2025, Chicago Research Center Inc is reported as receiving $5,819,646 in research payments, across 290 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $178,806 12
2024 Research $191,311 7
2023 Research $539,598 11
2022 Research $1,374,790 66
2021 Research $1,958,378 49
2020 Research $1,141,031 69
2019 Research $435,732 76

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sage Therapeutics, Inc. $3,121,187 108 payments
  2. Janssen Research & Development, LLC $1,898,133 101 payments
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. $588,472 6 payments
  4. Neurocrine Biosciences, Inc. $84,685 43 payments
  5. Teva Pharmaceuticals USA, Inc. $57,806 19 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $34,305 8 payments
  7. Vanda Pharmaceuticals Inc. $25,819 4 payments
  8. ITI, Inc. $9,238 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression $1,344,518 34 payments
  2. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With Sage-217 in Adult Subjects With Major Depressive Disorder $1,331,730 61 payments
  3. A Comparative Study of Sage-217 Plus Sertraline Versus Placebo Plus Sertraline in Adults With Major Depressive Disorder $856,531 21 payments
  4. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder $307,684 2 payments
  5. A Multi-Center, Randomized, Controlled Trial to Evaluate the Effectiveness of A Digital Therapeutic (CT-152) As Adjunctive Therapy in Adult Subjects Diagnosed With Major Depressive Disorder $294,517 3 payments
  6. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. $293,955 3 payments
  7. An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression $269,970 39 payments
  8. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of Sage-217 Compared to Placebo in Adult Subjects With Comorbid Major Depressive Disorder and Insomnia $220,135 7 payments
  9. A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 $192,517 11 payments
  10. 217-Mdd-303 $191,299 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record